SRI International Announces Taiwan Drug Development Initiative With Bridge Pharmaceuticals, Inc.

MENLO PARK, Calif., November 7, 2005 – SRI International announced today it has formed the SRI Taiwan R&D Center in Hsinchu to conduct a diverse range of scientific and technical activities in Taiwan. The Center will serve as a regional source of expertise to mature innovations for commercialization.

MORE ON THIS TOPIC